Allogene Therapeutics, Inc. (ALLO): Price and Financial Metrics


Allogene Therapeutics, Inc. (ALLO)

Today's Latest Price: $31.52 USD

0.29 (-0.91%)

Updated Nov 27 1:00pm

Add ALLO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ALLO Stock Price Chart Interactive Chart >

Price chart for ALLO

ALLO Price/Volume Stats

Current price $31.52 52-week high $55.00
Prev. close $31.81 52-week low $17.43
Day low $31.32 Volume 324,600
Day high $32.32 Avg. volume 818,078
50-day MA $35.17 Dividend yield N/A
200-day MA $34.33 Market Cap 4.42B

Allogene Therapeutics, Inc. (ALLO) Company Bio


Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is based in South San Francisco, California.


ALLO Latest News Stream


Event/Time News Detail
Loading, please wait...

ALLO Latest Social Stream


Loading social stream, please wait...

View Full ALLO Social Stream

Latest ALLO News From Around the Web

Below are the latest news stories about Allogene Therapeutics Inc that investors may wish to consider to help them evaluate ALLO as an investment opportunity.

Allogene Therapeutics' (ALLO) CEO David Chang on Q2 2020 Results - Earnings Call Transcript

Allogene Therapeutics, Inc. (ALLO) Q2 2020 Earnings Conference Call August 5, 2020 8:30 AM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive Vice President-Research and Development and Chief Medical Officer Eric Schmidt – Chief Financial Officer Conference...

SA Transcripts on Seeking Alpha | August 6, 2020

Earnings Scheduled For August 5, 2020

Companies Reporting Before The Bell • AmerisourceBergen Inc. (NYSE: ABC ) is expected to report quarterly earnings at $1.56 per share on revenue of $44.66 billion. • Advanced Energy Indus Inc. (NASDAQ: AEIS ) is expected to report quarterly earnings at $0.81 per share on revenue of $318.21 million, • ALLETE Inc. (NYSE: ALE ) is expected to report quarterly earnings at $0.67 per share on revenue of $290.75 million. • Allogene Therapeutics Inc. (NASDAQ: ALLO ) is expected to report earnings for its second quarter. • Ares Management Inc. (NYSE: ARES ) is estimated to report quarterly earnings at $0.38 per share on revenue of $343.00 million. • Astec Industries Inc. (NASDAQ: ASTE ) is estimated to report quarterly earnings at $0.05 per share on revenue of $228.97 million. • Athene Holding I...

Benzinga | August 5, 2020

4 Companies That Could Upend the Pharma Industry

Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.

Yahoo | July 29, 2020

Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics,…

GlobeNewswire | July 28, 2020

Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company's Novel Gene-Edited, iPSC-Derived Immune Cell Therapeutics

Notch Therapeutics Inc., a biotechnology company creating universally compatible, off-the-shelf T cell therapies for cancer and immune disorders from renewable stem cell sources, is pleased to announce the appointment of David Main as President and Chief Executive Officer.

Yahoo | July 20, 2020

Read More 'ALLO' Stories Here

ALLO Price Returns

1-mo -11.39%
3-mo -9.92%
6-mo -35.59%
1-year 11.85%
3-year N/A
5-year N/A
YTD 21.32%
2019 -3.53%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7387 seconds.